Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00493961 · ClinicalTrials.gov registry record · Phase 1

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

A Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT00493961 is a Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00493961, a Phase 1 study of Kallmann Syndrome and Idiopathic Hypogonadotropic Hypogonadism, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for 7 days.

Interventions

  • DRUG gonadotropin releasing hormone (GnRH)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 1999-01
Est. Completion 2009-11-17
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00493961

The ClinicalTrials.gov registry entry for NCT00493961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Kallmann Syndrome appearing as the primary indexed condition, and to 1 intervention - of which gonadotropin releasing hormone (GnRH) is the first listed.

NCT00493961 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00493961 about?

NCT00493961 is a clinical study titled "Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism". Men with Idiopathic Hypogonadotropic Hypogonadism (IHH) lack a hormone called gonadotropin releasing hormone (GnRH). This hormone is important for starting puberty, maintaining testosterone levels, and fertility. The purpose of this study is to research the effects of treating IHH men with GnRH for ...

What is the current status of trial NCT00493961?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 1999-01. Estimated completion is 2009-11-17.

What conditions does trial NCT00493961 study?

This clinical trial studies the following conditions: Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency.

What interventions are being tested in trial NCT00493961?

The interventions under investigation include: gonadotropin releasing hormone (GnRH) (DRUG).

Who is sponsoring clinical trial NCT00493961?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00493961 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kallmann Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.